Current evidence does not suggest an additional increase in the risk of skin cancers in IBD patients treated with combination therapy involving TNFα inhibitors and a thiopurine or methotrexate when compared to the cancer risks associated with monotherapy using either agent. This evidence concerns the gene TNF and skin cancer.